Get the Stockscreener App
1.00
0.99%
-0.01
After Hours:
1.00
Neurosense Therapeutics Ltd stock is traded at $1.00, with a volume of 95,763.
It is down -0.99% in the last 24 hours and down -2.91% over the past month.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
See More
Previous Close:
$1.01
Open:
$1.02
24h Volume:
95,763
Relative Volume:
0.30
Market Cap:
$33.11M
Revenue:
-
Net Income/Loss:
$-10.21M
P/E Ratio:
-1.7117
EPS:
-0.5842
Net Cash Flow:
-
1W Performance:
+14.94%
1M Performance:
-2.91%
6M Performance:
-10.71%
1Y Performance:
-13.58%
1-Day Range:
$0.9524
$1.05
1-Week Range:
$0.861
$1.06
52-Week Range:
$0.6801
$2.60
Neurosense Therapeutics Ltd Stock (NRSN) Company Profile
Name
Neurosense Therapeutics Ltd
Sector
Industry
Phone
-
Address
-
Compare NRSN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NRSN
Neurosense Therapeutics Ltd
|
1.00 | 33.44M | 0 | -10.21M | 0 | -0.5842 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Neurosense Therapeutics Ltd Stock (NRSN) Latest News
Aug Chart Watch: Is NeuroSense Therapeutics Ltd Equity Warrant benefiting from interest rate changesGlobal Markets & Real-Time Stock Price Movement Reports - baoquankhu1.vn
MACD Signal: Whats the fair value of NeuroSense Therapeutics Ltd stockAnalyst Upgrade & Weekly Momentum Picks - baoquankhu1.vn
Neurosense Therapeutics stock rises after securing Australian patent for PrimeC - Investing.com Nigeria
NeuroSense Wins Australian Patent to Extend PrimeC IP Protection Through 2042 - TipRanks
NeuroSense Expands Global IP Protection Strategy With Granted Australian Patent Covering PrimeC Composition - PR Newswire
Published on: 2026-02-09 14:28:13 - baoquankhu1.vn
Weekly Recap: Is NeuroSense Therapeutics Ltd Equity Warrant benefiting from interest rate changes2025 Macro Impact & AI Powered Market Entry Strategies - baoquankhu1.vn
Aug EndMonth: Is NeuroSense Therapeutics Ltd Equity Warrant showing insider buyingInsider Selling & Growth Focused Entry Point Reports - baoquankhu1.vn
Is now the right time to enter Tectonic Therapeutic IncMarket Growth Report & Daily Profit Maximizing Trade Tips - baoquankhu1.vn
Buyback Watch: Is HSDT a play on infrastructure spending2025 Volume Leaders & AI Powered Market Trend Analysis - baoquankhu1.vn
Insider Buy: Is SPGPRJ undervalued by DCF analysisJuly 2025 Price Swings & Weekly High Momentum Picks - baoquankhu1.vn
Aug Retail: Will TILE benefit from seasonality2025 Valuation Update & Daily Growth Stock Tips - baoquankhu1.vn
Short Covering: Can SNVPRE expand into new marketsOil Prices & Verified Momentum Stock Watchlist - baoquankhu1.vn
Breakouts Watch: Is NeuroSense Therapeutics Ltd Equity Warrant showing insider buying2025 Winners & Losers & Reliable Momentum Entry Alerts - baoquankhu1.vn
Valuation Update: What is DMACs revenue forecastEarnings Overview Report & AI Based Buy/Sell Signal Reports - baoquankhu1.vn
NeuroSense’s ALS drug PrimeC shows success in phase 2b, eyes final trial - MSN
New Alzheimer’s treatment from NeuroSense gets U.S. patent through 2043 - Stock Titan
Analyst Calls: Is NeuroSense Therapeutics Ltd gaining market sharePortfolio Value Report & Proven Capital Preservation Methods - baoquankhu1.vn
Is NeuroSense Therapeutics Ltd. a momentum stockFed Meeting & Long Hold Capital Preservation Tips - bollywoodhelpline.com
Portfolio Shifts: Is NeuroSense Therapeutics Ltd Equity Warrant showing insider buyingJuly 2025 Update & Long-Term Capital Growth Ideas - baoquankhu1.vn
Big Picture: What are NeuroSense Therapeutics Ltd Equity Warrants recent SEC filings showingQuarterly Investment Review & Free High Return Stock Watch Alerts - baoquankhu1.vn
Weekly Trades: Is NeuroSense Therapeutics Ltd Equity Warrant benefiting from interest rate changes2025 Volatility Report & Growth Focused Stock Reports - baoquankhu1.vn
Ideas Watch: Will NeuroSense Therapeutics Ltd face regulatory challengesWeekly Trend Report & Technical Pattern Based Signals - baoquankhu1.vn
Weekly Trades: Why is NeuroSense Therapeutics Ltd stock going downInsider Selling & Daily Profit Focused Screening - baoquankhu1.vn
Aug Highlights: Is SNOA likely to announce a buybackIPO Watch & Fast Entry High Yield Tips - baoquankhu1.vn
Earnings Recap: Will NeuroSense Therapeutics Ltd Equity Warrant stock go up in YEARJuly 2025 Outlook & Technical Entry and Exit Tips - baoquankhu1.vn
RSI Check: Why NeuroSense Therapeutics Ltd stock appeals to analysts2025 Breakouts & Breakdowns & Daily Profit Focused Stock Screening - Bộ Nội Vụ
Bear Alert: Can NeuroSense Therapeutics Ltd stock beat analyst upgradesJuly 2025 Price Swings & Weekly High Momentum Picks - Bộ Nội Vụ
Risk Hedge: Is NeuroSense Therapeutics Ltd stock a good choice for value investorsJuly 2025 PostEarnings & Verified Swing Trading Watchlists - Bộ Nội Vụ
How NeuroSense Therapeutics Ltd. stock benefits from tech adoptionEarnings Recap Summary & Verified Entry Point Signals - ulpravda.ru
Why NeuroSense Therapeutics Ltd. Equity Warrant stock appeals to analystsProfit Target & Weekly High Return Stock Forecasts - Улправда
Will NeuroSense Therapeutics Ltd. stock remain a Wall Street favorite2025 Volume Leaders & Stepwise Entry and Exit Trade Signals - Улправда
Technical Analysis: What risks investors should watch in NeuroSense Therapeutics Ltd stockRate Cut & Verified Stock Trade Ideas - Bộ Nội Vụ
World-Renowned Alzheimer's Expert Prof. Steven Arnold Joins NeuroSense SAB - Sahm
What risks investors should watch in NeuroSense Therapeutics Ltd. stockForecast Cut & Precise Swing Trade Entry Alerts - ulpravda.ru
Is NeuroSense Therapeutics Ltd. stock resilient to inflationGlobal Markets & Weekly High Momentum Picks - Улправда
Will NeuroSense Therapeutics Ltd. Equity Warrant stock recover faster than peersJuly 2025 WrapUp & Weekly Market Pulse Updates - Улправда
NeuroSense Therapeutics Ltd.Ordinary Shares (NQ: NRSN - FinancialContent
How NeuroSense Therapeutics Ltd. Equity Warrant stock responds to policy changesWeekly Risk Summary & Weekly High Potential Alerts - Улправда
Can NeuroSense Therapeutics Ltd. stock resist sector downturnsWeekly Investment Recap & High Return Stock Watch Alerts - Улправда
Trading Recap: Will NeuroSense Therapeutics Ltd. (H1Z) stock justify high valuation2025 Price Momentum & Fast Gain Stock Tips - Улправда
Can NeuroSense Therapeutics Ltd. stock continue upward trendBreakout Watch & Free AI Powered Buy and Sell Recommendations - Улправда
Is NeuroSense Therapeutics Ltd. Equity Warrant stock a good choice for value investors2025 Support & Resistance & Precise Swing Trade Alerts - Улправда
NeuroSense Therapeutics Ltd. Appoints Prof. Steven E. Arnold to Scientific Advisory Board - MarketScreener
Hedge Fund Bets: How NeuroSense Therapeutics Ltd. Equity Warrant stock performs after earningsJuly 2025 Intraday Action & Weekly Setup with ROI Potential - Улправда
NeuroSense Shareholders Approve Equity Grants to Directors and CEO to Preserve Cash - TipRanks
How NeuroSense Therapeutics Ltd. stock compares to growth peers2026 world cup usa national team semifinals defensive leaders set piece tactics match prediction analysis - ulpravda.ru
NeuroSense Therapeutics (NASDAQ:NRSN) Upgraded by Wall Street Zen to Hold Rating - Defense World
NeuroSense Therapeutics Ltd. (NASDAQ:NRSNW) Short Interest Down 15.5% in December - Defense World
NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Weekly Buzz: FDA OKs Roche's Lunsumio VELO; It's No For Tolbrutinib; BioMarin, SNY Open Wallets - RTTNews
Neurosense Therapeutics Ltd Stock (NRSN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):